Second Study Affirms Superiority of iMDx GraftAssure Assay's Proprietary dd-cfDNA Combination Model Score [Yahoo! Finance]
Insight Molecular Diagnostics Inc. (IMDX)
Company Research
Source: Yahoo! Finance
Insight Molecular Diagnostics Inc. New data supports GraftAssure commercialization efforts Multi-center study featured 249 biopsy-matched patients Proprietary “Combination Model” score outperformed percentage-only measures of dd-cfDNA Reinforces data presented at World Transplant Congress in 2025 NASHVILLE, Tenn., March 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx”) today highlighted the publication of a new peer-reviewed study demonstrating the potential superiority of the company's flagship GraftAssure TM assay technology. The study, published in Transplant International, and titled “Donor-Derived Cell-Free DNA as a Non-Invasive Readout of Activity Across the Rejection Continuum,” was conducted by investigators from Heidelberg University Hospital and Charité – Universitätsmedizin Berlin and included iMDx scientist authors. This new study, combined with data presented at World Transplant Congress in 2025, point to growing clinic
Show less
Read more
Impact Snapshot
Event Time:
IMDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMDX alerts
High impacting Insight Molecular Diagnostics Inc. news events
Weekly update
A roundup of the hottest topics
IMDX
News
- iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- iMDx to Release Fourth Quarter 2025 Results on March 26, 2026 and Attend Needham Virtual Healthcare ConferenceGlobeNewswire
- How Insight Molecular Diagnostics (IMDX) Story Is Shifting With New Capital And GraftAssureDx Milestones [Yahoo! Finance]Yahoo! Finance
- Second Study Affirms Superiority of iMDx GraftAssure Assay’s Proprietary dd-cfDNA Combination Model ScoreGlobeNewswire
- Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission [Yahoo! Finance]Yahoo! Finance
IMDX
Sec Filings
- 2/26/26 - Form 8-K
- 2/12/26 - Form SCHEDULE
- 2/12/26 - Form 4
- IMDX's page on the SEC website